These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2046473)

  • 1. Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine.
    Broly F; Vandamme N; Caron J; Libersa C; Lhermitte M
    Life Sci; 1991; 48(26):PL123-8. PubMed ID: 2046473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
    Turgeon J; Fiset C; Giguère R; Gilbert M; Moerike K; Rouleau JR; Kroemer HK; Eichelbaum M; Grech-Bélanger O; Bélanger PM
    J Pharmacol Exp Ther; 1991 Nov; 259(2):789-98. PubMed ID: 1941626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
    Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
    J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K; Gram LF; Haghfelt T; Bertilsson L
    Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
    Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.
    Lledó P; Abrams SM; Johnston A; Patel M; Pearson RM; Turner P
    Eur J Clin Pharmacol; 1993; 44(1):63-7. PubMed ID: 8436157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
    Dalén P; Dahl M; Andersson K; Bertilsson L
    Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
    Ayesh R; Dawling S; Hayler A; Oates NS; Cholerton S; Widdop B; Idle JR; Smith RL
    Chirality; 1991; 3(1):14-8. PubMed ID: 2039678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.
    Leemann T; Dayer P; Meyer UA
    Eur J Clin Pharmacol; 1986; 29(6):739-41. PubMed ID: 3709620
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects.
    Paczkowski D; Sadowski Z; Filipek M; Koliński P
    Pol J Pharmacol Pharm; 1990; 42(4):365-75. PubMed ID: 2097598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.
    Leemann TD; Devi KP; Dayer P
    Eur J Clin Pharmacol; 1993; 45(1):65-71. PubMed ID: 8405032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mexiletine metabolism in vitro by human liver.
    Broly F; Libersa C; Lhermitte M
    Drug Metab Dispos; 1990; 18(3):362-8. PubMed ID: 1974200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine.
    Labbé L; Abolfathi Z; Robitaille NM; St-Maurice F; Gilbert M; Turgeon J
    Ther Drug Monit; 1999 Apr; 21(2):191-9. PubMed ID: 10217339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes.
    Broly F; Libersa C; Lhermitte M; Dupuis B
    Biochem Pharmacol; 1990 Mar; 39(6):1045-53. PubMed ID: 2322292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
    Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
    Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
    Muralidharan G; Hawes EM; McKay G; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1991; 41(5):471-4. PubMed ID: 1761076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
    Inaba T; Tyndale RE; Mahon WA
    Br J Clin Pharmacol; 1986 Aug; 22(2):199-200. PubMed ID: 3756068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.